单次玻璃体腔注射雷珠单抗联合激光治疗视网膜分支静脉阻塞继发黄斑水肿

目的：观察单次玻璃体腔注射雷珠单抗联合激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿的临床疗效。方法：回顾性系列病例研究。选择2014 年6月至2016 年12 月在台州市眼科医院经荧光素眼底血管造影确诊的视网膜分支静脉阻塞继发黄斑水肿的患者52例（52眼），根据是否联合雷珠单抗治疗分为单纯激光组和联合治疗组，联合治疗组又根据接受雷珠单抗及激光治疗的先后顺序分为先激光组和后激光组。分别测量并记录患者治疗前，治疗后1、6 个月最佳矫正视力（BCVA）及黄斑中心凹厚度（CMT）。采用重复测量方差分析、单因素方差分析和配对t检验对数据进行统计学分析。结果：治疗前，治疗后1、6个月3组间BCVA总体差异有统计学意义（F=18.28，P=0.011）。治疗后1、6个月同一时间点3 组间BCVA比较，单纯激光组分别低于先激光组和后激光组（P < 0.01）。3 组治疗后6 个月BCVA较治疗前均有所提高，差异均有统计学意义（t=8.49、14.57、20.12，P < 0.01）。治疗前，治疗后1、6 个月3 组间CMT值总体差异有统计学意义（F=5.72，P=0.025）。治疗后1、6 个月同一时间点3 组间CMT值比较，单纯激光组分别大于先激光组和后激光组（P < 0.01）。3 组治疗后1、6 个月较治疗前CMT值均有所下降，差异均有统计学意义（P < 0.01）。结论：单次玻璃体腔注射雷珠单抗联合视网膜激光光凝治疗可有效减轻视网膜分支静脉阻塞继发黄斑水肿，提高患者的视力，其作用较单纯激光光凝治疗更加明显。

Single Intravitreal Injection of Ranibizumab with Laser Photocoagulation for Macular Edema Following Branch Retinal Vein Occlusion

Objective: To assess the efficacy of single intravitreal injection of ranibizumab with laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 52 patients (52 eyes) during June 2014 to December 2016 at Taizhou Municipal Hospital with macular edema secondary to BRVO were diagnosed by fundus fluorescence angiography. The patients were divided into two groups, one receiving laser photocoagulation alone and the other receiving a single intravitreal injection of ranibizumab. The injection group was further divided into two groups,one receiving the injection before laser therapy and one receiving afterwards. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before the therapy and at one and six months afterwards. Repeated measurement analysis of variance, one-way analysis of variance, and paired t-tests were used to analyze the data. Results: Before the therapy, and at one and six months after therapy,the total difference of BCVA among the three groups was statistically significant (F=18.28, P=0.011).Objective: To assess the efficacy of single intravitreal injection of ranibizumab with laser photocoagulation for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 52 patients (52 eyes) during June 2014 to December 2016 at Taizhou Municipal Hospital with macular edema secondary to BRVO were diagnosed by fundus fluorescence angiography. The patients were divided into two groups, one receiving laser photocoagulation alone and the other receiving a single intravitreal injection of ranibizumab. The injection group was further divided into two groups,one receiving the injection before laser therapy and one receiving afterwards. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before the therapy and at one and six months afterwards. Repeated measurement analysis of variance, one-way analysis of variance, and paired t-tests were used to analyze the data. Results: Before the therapy, and at one and six months after therapy,the total difference of BCVA among the three groups was statistically significant (F=18.28, P=0.011).